Patent Assignment
Reel/Frame 072872/0076
Change of Name
Recorded: 2025-09-23
Pages: 10
Assignor
BEIGENE SWITZERLAND GMBH
Executed: 2025-05-05
Assignee
BEONE MEDICINES I GMBH
AESCHENGRABEN 27, BASEL, 4051, SWITZERLAND
Covered Properties
(67)
Pyrazolopyridinone Compounds
Application:
18/603,755 →
Publication:
US 2024/0270751
Pyrazolopyridinone Compounds
Application:
18/431,626 →
Publication:
US 2024/0300951
3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof
Application:
18/743,968 →
Publication:
US 2025/0154107
Solid Forms of BCL-2 Inhibitors, Method of Preparation, and Use Thereof
Application:
18/589,022 →
Publication:
US 2024/0317743
SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS
Application:
19/269,868 →
Methods for Treating Primary Membranous Nephropathy
Application:
19/188,946 →
Publication:
US 2025/0249010
Oral Solid Tablet Comprising Bruton's Tyrosine Kinase Inhibitor and Preparation Method Therefor
Application:
19/026,988 →
Publication:
US 2025/0152594
Methods of Treating Multiple Myeloma Using Bcl-2 Inhibitor
Application:
19/030,242 →
Publication:
US 2025/0161279
Solid Forms Comprising (S)-7-(1-Acryloylpiperidin-4-Yl)-2-(4-Phenoxyphenyl)-4,5,6,7-Tetrahydropyrazolo[1,5-a]Pyrimidine-3-Carboxamide, and Oxalic Acid, Compositions and Methods of Use Thereof
Application:
19/062,656 →
Methods of Treating Myeloid Malignancies Using Bcl-2 Inhibitor
Application:
18/938,467 →
Publication:
US 2025/0057821
CRYSTALLINE FORM OF (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRA-HYDROPYRAZOLO[1,5-a]PYRIMIDINE-3-CARBOXAMIDE, PREPARATION, AND USES THEREOF
Application:
18/810,987 →
Publication:
US 2024/0409546
Methods of Treating B-Cell Proliferative Disorder
Application:
18/541,928 →
Publication:
US 2024/0131030
Methods of Treating B-Cell Malignancy Using Bcl-2 Inhibitor
Application:
18/524,170 →
Publication:
US 2024/0122932
Kras G12C Inhibitors
Application:
18/261,629 →
Publication:
US 2024/0166660
Bridged Compounds as Kras G12D Inhibitor and Degrader and the Use Thereof
Application:
18/260,649 →
Publication:
US 2024/0140957
Methods of Treating Chronic Active Antibody-Mediated Rejection Using Btk Inhibitors
Application:
18/263,448 →
Publication:
US 2024/0139195
Bridged Compounds as Kras G12D Inhibitor and Degrader and the Use Thereof
Application:
18/260,654 →
Publication:
US 2024/0092803
Methods of Treating Systemic Lupus Erythematosus Using Btk Inhibitors
Application:
18/253,720 →
Publication:
US 2025/0073238
Methods of treatment of B cell cancer with Bruton's tyrosine kinase inhibitors
Application:
18/322,542 →
Publication:
US 2023/0364096
Oral Capsule and Preparation Method Therefor
Application:
18/099,319 →
Publication:
US 2023/0149411
Methods of Treating Dlbcl Using Btk Inhibitors and Combinations Thereof
Application:
17/802,111 →
Publication:
US 2023/0089557
Oral Capsule and Preparation Method Therefor
Application:
17/617,531 →
Publication:
US 2022/0241285
Compounds for the Degradation of Egfr Kinase
Application:
19/204,126 →
Publication:
US 2025/0332266
Compounds for the Degradation of EGFR Kinase
Application:
18/676,648 →
Publication:
US 2024/0342292
Methods of Synthesis of Chiral 3,5-Disubstituted Morpholine Compounds and Intermediates Useful Therein
Application:
18/680,922 →
Publication:
US 2025/0066313
Compounds for the Degradation of EGFR Kinase
Application:
18/678,898 →
Publication:
US 2024/0425523
5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5
Application:
18/617,913 →
Publication:
US 2024/0368177
(R)-Glutarimide CRBN Ligands and Methods of Use
Application:
18/391,154 →
Publication:
US 2024/0207267
EGFR Degraders and Associated Methods of Use
Application:
18/497,586 →
Publication:
US 2024/0131167
Egfr Degraders and Methods of Use
Application:
18/264,881 →
Publication:
US 2024/0165243
Preparation Methods for a Highly Concentrated PD1 Antibody Solution by Ultrafiltration/Diafiltration (Uf/Df)
Application:
19/012,602 →
Publication:
US 2025/0197445
Stable High Concentration Sodium Chloride Formulations Containing Pd-1 Antibody and Methods of Use Thereof
Application:
18/910,935 →
Publication:
US 2025/0084168
Anti-Galectin-9 Antibodies and Therapeutic Uses Thereof
Application:
18/697,500 →
Publication:
US 2025/0269019
Anti-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
Anti-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
Anti-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
Anti-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
Anti-PD1 Antibodies and Their Use as Therapeutics and Diagnostics
Patent:
8,735,553 →
Application:
14/076,214 →
KAT6 Inhibitors
Application:
19/093,521 →
Publication:
US 2025/0304535
KAT6 Inhibitors
Application:
18/897,194 →
Publication:
US 2025/0122152
Pyrrolo[2, 3-b]Pyrazine-Based Bifunctional Compounds as HPK1 Degraders and the Use Thereof
Application:
18/422,518 →
Publication:
US 2024/0228497
Process for Preparing a Parp Inhibitor, Crystalline Forms, and Uses Thereof
Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors
Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors
Fused Tetra or Penta-Cyclic Dihydrodiazepinocarbazolones as Parp Inhibitors
Gamma Delta T Cell Compositions and Methods of Use
Application:
19/080,477 →
Publication:
US 2025/0290040
Anti-Tim-3 Antibodies and Use Thereof
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application:
19/049,939 →
Publication:
US 2025/0262222
Heterocyclic Compounds, Compositions Thereof, and Methods of Treatment Therewith
Application:
19/049,918 →
Publication:
US 2025/0250287
Heterocyclic Compounds
Application:
18/733,421 →
Publication:
US 2024/0327417
Ligand-Drug Conjugate of Exatecan Analogue, and Medical Use Thereof
Application:
19/089,217 →
Publication:
US 2025/0295798
MUC1 and CD16A Antibodies and Methods of Use
Application:
18/826,629 →
Publication:
US 2025/0075002
Anti-CEA Antibody Drug Conjugates and Methods of Use
Application:
18/940,225 →
Publication:
US 2025/0115677
Anti-Cea and Anti-CD137 Multispecific Antibodies and Methods of Use
Application:
18/513,223 →
Publication:
US 2024/0190989
Anti-Cea Antibodies and Methods of Use
Application:
18/513,255 →
Publication:
US 2024/0190990
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Application:
18/758,176 →
Publication:
US 2024/0366769
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Application:
18/758,275 →
Publication:
US 2024/0366770
Degradation of Bruton's Tyrosine Kinase (Btk) by Conjugation of Btk Inhibitors with E3 Ligase Ligand and Methods of Use
Application:
18/259,858 →
Publication:
US 2024/0246977
Formulations Containing Anti-Tigit Antibody and Methods of Use Thereof
Application:
19/176,565 →
Publication:
US 2025/0304682
Anti-CLDN6 and Anti-CD3 Multispecific Antibodies and Methods of Use
Application:
18/620,208 →
Publication:
US 2024/0301061
Anti-CD3 Multispecific Antibodies and Methods of Use
Application:
18/620,439 →
Publication:
US 2024/0301062
Anti-CD137 Antibodies and Methods of Use
Application:
18/513,169 →
Publication:
US 2024/0209106
Anti-Tigit Antibodies and Their Use as Therapeutics and Diagnostics
Application:
17/675,515 →
Publication:
US 2022/0251195
Anti-Tigit Antibodies and Their Use as Therapeutics and Diagnostics
Anti-Tigit Antibodies and Their Use as Therapeutics and Diagnostics
Anti-Pvrig Antibodies and Methods of Use
Application:
19/048,629 →
Publication:
US 2025/0326842
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 23, 2022
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 060292/0066 →
Assignment of Assignor's Interest
Jun 23, 2022
From: WANG, YIPING; GUO, YUANJING
To: BEIGENE, LTD.
Reel/Frame 060292/0020 →
Assignment of Assignor's Interest
Feb 2, 2023
From: YU, YILING; LIU, YANG; WANG, WEIGE; YAO, HUI
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 062575/0609 →
Assignment of Assignor's Interest
May 23, 2023
From: HU, NAN; LI, SHURAN; SONG, XIAOMIN; YAO, ZHEN
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 063729/0679 →
Assignment of Assignor's Interest
Jul 7, 2023
From: JI, QI; YU, CHAO; WANG, CE; SUN, HANZI
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064181/0943 →
Assignment of Assignor's Interest
Jul 7, 2023
From: JI, QI; YU, CHAO; WANG, CE; SUN, HANZI
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064182/0471 →
Assignment of Assignor's Interest
Jul 14, 2023
From: ZHANG, GUOLIANG; MIAO, JIANZHUANG; WANG, CE; NI, ZHIKUN
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064263/0942 →
Assignment of Assignor's Interest
Jul 19, 2023
From: WANG, YIPING; GUO, YUANJING
To: BEIGENE, LTD.
Reel/Frame 064310/0407 →
Assignment of Assignor's Interest
Jul 19, 2023
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064310/0412 →
Assignment of Assignor's Interest
Jul 28, 2023
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064420/0925 →
Assignment of Assignor's Interest
Jul 28, 2023
From: HU, NAN; WANG, LAI; SONG, JING; ZHANG, TONG
To: BEIGENE, LTD.
Reel/Frame 064424/0079 →
Assignment of Assignor's Interest
Jul 28, 2023
From: ZHOU, JIAJUN
To: BEIGENE, LTD.
Reel/Frame 064420/0841 →
Assignment of Assignor's Interest
Aug 2, 2023
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 064463/0224 →
Assignment of Assignor's Interest
Feb 16, 2024
From: PAIK, JASON; SALMI, TOMMI; OU, YING
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 066477/0422 →
Assignment of Assignor's Interest
Feb 16, 2024
From: TAKAI, MOTOHISA
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 066477/0499 →
Assignment of Assignor's Interest
Aug 20, 2024
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 068338/0663 →
Assignment of Assignor's Interest
Aug 20, 2024
From: ZHANG, GUOLIANG; NI, ZHIKUN; MIAO, JIANZHUANG; WANG, CE
To: BEIGENE, LTD.
Reel/Frame 068338/0559 →
Assignment of Assignor's Interest
Aug 20, 2024
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 068338/0052 →
Assignment of Assignor's Interest
Aug 20, 2024
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 068335/0896 →
Assignment of Assignor's Interest
Aug 20, 2024
From: PHARMARESOURCES (SHANGHAI) CO., LTD.
To: BEIGENE, LTD.
Reel/Frame 068335/0784 →
Assignment of Assignor's Interest
Aug 20, 2024
From: SUN, YUANGMING; ZHANG, QIN; XU, ZHONGMING; YANG, JIANGZHANG
To: PHARMARESOURCES (SHANGHAI) CO., LTD.
Reel/Frame 068335/0371 →
Assignment of Assignor's Interest
Aug 20, 2024
From: LEI, BAILIN; LIU, HUAQING; HAN, SONGZHE; ZHAO, YIZHOU
To: BEIGENE, LTD.
Reel/Frame 068337/0966 →
Assignment of Assignor's Interest
Aug 20, 2024
From: LAI, XINZHONG; DEERBERG, JOERG
To: BEIGENE, LTD.
Reel/Frame 068335/0152 →
Assignment of Assignor's Interest
Aug 20, 2024
From: BEIGENE, LTD.
To: BEIGENE SWITZERLAND GMBH
Reel/Frame 068334/0169 →
Assignment of Assignor's Interest
Aug 20, 2024
From: HILGER, JAMES; HUANG, JANE; SIMPSON, DAVID
To: BEIGENE, LTD.
Reel/Frame 068334/0113 →